

Australia's Telix starts US trial

18 April 2022 | News

First patients Dosed with Illuccix - Telix's approved prostate cancer imaging agent



Australia's Telix Pharmaceuticals has announced first commercial doses of its prostate cancer imaging agent, Illuccix[®] (kit for preparation of gallium Ga-68 gozetotide injection), also known as ⁶⁸Ga-PSMA-11 injection.

As Illuccix rolls out nationally across the United States, physicians in Indianapolis (Indiana University School of Medicine), New York City, and Seattle are among the first to administer this new PSMA PET^[2] imaging agent that can help health care professionals (HCPs) diagnose the stage and spread of disease – an important step for the optimal care of men with prostate cancer.

Illuccix is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer with:

- suspected metastasis who are candidates for initial definitive therapy;
- suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Illuccix is now widely available across the United States, significantly improving patient access to PSMA PET imaging. PSMA PET imaging is emerging as a standard of care in the U.S. having been included in latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer.